ARS Pharmaceuticals (SPRY) Competitors

Avidity Biosciences (NASDAQ:RNA) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

Is RNA or SPRY more profitable?

ARS Pharmaceuticals has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. ARS Pharmaceuticals' return on equity of -22.56% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-2,772.45%	-27.66%	-24.56%
ARS Pharmaceuticals	N/A	-22.56%	-21.82%

Does the MarketBeat Community prefer RNA or SPRY?

Avidity Biosciences received 135 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 82.61% of users gave ARS Pharmaceuticals an outperform vote while only 67.25% of users gave Avidity Biosciences an outperform vote.

Company	Underperform	Outperform
Avidity Biosciences	Outperform Votes 154 67.25%	Underperform Votes 75 32.75%
ARS Pharmaceuticals	Outperform Votes 19 82.61%	Underperform Votes 4 17.39%

Which has more volatility & risk, RNA or SPRY?

Avidity Biosciences has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Which has higher valuation & earnings, RNA or SPRY?

ARS Pharmaceuticals has lower revenue, but higher earnings than Avidity Biosciences. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$9.56M	544.76	-$212.22M	-$2.88	-15.16
ARS Pharmaceuticals	$30K	43,892.97	-$54.37M	-$0.51	-26.57

Does the media favor RNA or SPRY?

In the previous week, ARS Pharmaceuticals had 10 more articles in the media than Avidity Biosciences. MarketBeat recorded 25 mentions for ARS Pharmaceuticals and 15 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.38 beat ARS Pharmaceuticals' score of 0.34 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of RNA or SPRY?

68.2% of ARS Pharmaceuticals shares are held by institutional investors. 3.7% of Avidity Biosciences shares are held by insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts recommend RNA or SPRY?

Avidity Biosciences presently has a consensus target price of $63.22, suggesting a potential upside of 44.84%. ARS Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 77.12%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Avidity Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
ARS Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33

Summary

ARS Pharmaceuticals beats Avidity Biosciences on 13 of the 19 factors compared between the two stocks.